1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > Lymphoblastic Lymphoma - Pipeline Review, H1 2013

Lymphoblastic Lymphoma - Pipeline Review, H1 2013

  • June 2013
  • -
  • Global Markets Direct
  • -
  • 31 pages

Lymphoblastic Lymphoma - Pipeline Review, H1 2013


Summary


Global Markets Direct’s, 'Lymphoblastic Lymphoma - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Lymphoblastic Lymphoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Lymphoblastic Lymphoma. Lymphoblastic Lymphoma - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


Scope


- A snapshot of the global therapeutic scenario for Lymphoblastic Lymphoma.
- A review of the Lymphoblastic Lymphoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Lymphoblastic Lymphoma pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.


Reasons to buy


- Identify and understand important and diverse types of therapeutics under development for Lymphoblastic Lymphoma.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Lymphoblastic Lymphoma pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Lymphoblastic Lymphoma - Pipeline Review, H1 2013
Table of Contents 2
List of Tables 3
List of Figures 3
Introduction 4
Global Markets Direct Report Coverage 4
Lymphoblastic Lymphoma Overview 5
Therapeutics Development 6
An Overview of Pipeline Products for Lymphoblastic Lymphoma 6
Lymphoblastic Lymphoma Therapeutics under Development by Companies 8
Mid Clinical Stage Products 9
Comparative Analysis 9
Early Clinical Stage Products 10
Comparative Analysis 10
Lymphoblastic Lymphoma Therapeutics - Products under Development by Companies 11
Lymphoblastic Lymphoma Therapeutics - Products under Investigation by Universities/Institutes 12
Companies Involved in Lymphoblastic Lymphoma Therapeutics Development 13
Bristol-Myers Squibb Company 13
Sanofi-Aventis 14
Lymphoblastic Lymphoma - Therapeutics Assessment 15
Assessment by Monotherapy Products 15
Assessment by Route of Administration 16
Assessment by Molecule Type 18
Drug Profiles 20
SAR-245409 - Drug Profile 20
Product Description 20
Mechanism of Action 20
RandD Progress 20
BMS-906024 - Drug Profile 22
Product Description 22
Mechanism of Action 22
RandD Progress 22
Lymphoblastic Lymphoma Therapeutics - Drug Profile Updates 23
Lymphoblastic Lymphoma Therapeutics - Discontinued Products 24
Lymphoblastic Lymphoma Therapeutics - Dormant Products 25
Lymphoblastic Lymphoma - Product Development Milestones 26
Featured News and Press Releases 26
Dec 13, 2011: Immunomedics Announces Results From Phase II Trial Of Epratuzumab At Hematology Conference 26
Dec 11, 2011: Micromet's Blinatumomab Produces Durable Responses in Patients with Relapsed Diffuse Large B Cell Lymphoma 26
Dec 05, 2010: Pharmacyclics Reports Positive Results From Phase I Study Of PCI-32765 At ASH Annual Meeting 28
Appendix 30
Methodology 30
Coverage 30
Secondary Research 30
Primary Research 30
Expert Panel Validation 30
Contact Us 31
Disclaimer 31

List of Tables


Number of Products Under Development for Lymphoblastic Lymphoma, H1 2013 6
Products under Development for Lymphoblastic Lymphoma - Comparative Analysis, H1 2013 7
Number of Products under Development by Companies, H1 2013 8
Comparative Analysis by Mid Clinical Stage Development, H1 2013 9
Comparative Analysis by Early Clinical Stage Development, H1 2013 10
Products under Development by Companies, H1 2013 11
Products under Investigation by Universities/Institutes, H1 2013 12
Bristol-Myers Squibb Company, H1 2013 13
Sanofi-Aventis, H1 2013 14
Assessment by Monotherapy Products, H1 2013 15
Assessment by Stage and Route of Administration, H1 2013 17
Assessment by Stage and Molecule Type, H1 2013 19
Lymphoblastic Lymphoma Therapeutics - Drug Profile Updates 23
Lymphoblastic Lymphoma Therapeutics - Discontinued Products 24
Lymphoblastic Lymphoma Therapeutics - Dormant Products 25

List of Figures


Number of Products under Development for Lymphoblastic Lymphoma, H1 2013 6
Products under Development for Lymphoblastic Lymphoma - Comparative Analysis, H1 2013 7
Products under Development by Companies, H1 2013 8
Mid Clinical Stage Products, H1 2013 9
Early Clinical Stage Products, H1 2013 10
Assessment by Monotherapy Products, H1 2013 15
Assessment by Route of Administration, H1 2013 16
Assessment by Stage and Route of Administration, H1 2013 17
Assessment by Molecule Type, H1 2013 18
Assessment by Stage and Molecule Type, H1 2013 19

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98) - Pipeline Review, H2 2016

Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • October 2016
  • by Global Markets Direct

Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Histone Deacetylase 2 ...

Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) - Pipeline Review, H2 2016

Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • October 2016
  • by Global Markets Direct

Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) - Pipeline ...

Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) - Pipeline Review, H2 2016

Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • December 2016
  • by Global Markets Direct

Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Interleukin 1 Receptor Associated ...


ref:plp2013

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.